FHTX vs NRIX
FHTX: Foghorn Therapeutics is a clinical-stage biotech developing precision medicines by targeting the chromatin regulatory system to correct abnormal gene expression in cancer and other diseases. NRIX: Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate bexobrutideg in CLL and partnerships spanning Roche, Gilead, and Sanofi.
Side-by-side fundamentals
| Metric | FHTX | NRIX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $1.99 | $22.21 | |
| Market cap | $118M | $2.3B | |
| Net margin FY2025, SEC XBRL | -240.3% | -314.9% | FHTX higher |
| Operating margin FY2025, SEC XBRL | -279.5% | -340.2% | FHTX higher |
| ROE FY2025, SEC XBRL | n/a | -49.1% | |
| ROA FY2025, SEC XBRL | -37.5% | -38.4% | FHTX higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-03 | +52.0% | -58.4% | FHTX higher |
| Revenue CAGR (3y) SEC XBRL | +17.1% | +29.5% | NRIX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.59 | 1.33 | |
| 1-year return as of 2026-10-08 close | -55.8% | +122.5% | NRIX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.